Results 41 to 50 of about 2,693 (199)

Preferential Effects of Cariprazine on Counteracting the Disruption of Social Interaction and Decrease in Extracellular Dopamine Levels Induced by the Dopamine D3 Receptor Agonist, PD-128907 in Rats: Implications for the Treatment of Negative and Depressive Symptoms of Psychiatric Disorders

Frontiers in Psychiatry, 2022
The negative and cognitive symptoms of schizophrenia and related disorders may be due to reduced dopaminergic tone in cortical brain areas. Alteration in the function of dopamine (DA) D3 receptors may play a role in this cortical hypofunctionality and ...
Jan Kehr, Jan Kehr, Fu-Hua Wang, Fumio Ichinose, Shimako Yoshitake, Shimako Yoshitake, Bence Farkas, Béla Kiss, Nika Adham   +8 more
doaj   +1 more source

Tolerability of cariprazine in the early stage of schizophrenia: A pooled, post-hoc analysis of 4 phase ii/iii double-blind placebo-controlled trials

European Psychiatry, 2021
Introduction In the early stage of schizophrenia (first 5 years), the most important clinical target besides symptom control is relapse prevention as each relapse significantly decreases the possibility of preferable long-term outcomes.
Z.B. Dombi, K. Acsai, Á. Barabássy, B. Sebe, I. Laszlovszky, G. Vass, B. Szatmári, M. Patel, W. Earley, G. Németh   +9 more
doaj   +1 more source

Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel

Annals of General Psychiatry, 2020
Background Management of schizophrenia is sub-optimal in many patients. Targeting negative symptoms, among the most debilitating aspects of schizophrenia, together with positive symptoms, can result in significant functional benefits and dramatically ...
Andrea Fagiolini, José Ángel Alcalá, Thomas Aubel, Wojciech Bienkiewicz, Mats Magnus Knut Bogren, Joaquim Gago, Giancarlo Cerveri, Michael Colla, Francisco Collazos Sanchez, Alessandro Cuomo, Frieling Helge, Eduardo Iacoponi, Per-Axel Karlsson, Pradeep Peddu, Mauro Pettorruso, Henrique Jorge Ramos Pereira, Johan Sahlsten Schölin, Ingo Bernd Vernaleken   +17 more
doaj   +1 more source

Cariprazine Orodispersible Tablet: A New Formulation for Cariprazine

Pharmacopsychiatry
Abstract IntroductionCariprazine is an atypical dopamine receptor partial agonist antipsychotic available in the form of capsules. Although capsules are one of the most desirable routes of administration, there are certain situations (e.
Meszár, Viktória, Magyar, Gabriella, Pásztor, Gabriella Mészárosné, Szatmári, Balázs, Péter, Krisztina, Marton, Lívia, Dombi, Zsófia B., Barabássy, Ágota   +7 more
openaire   +2 more sources

Cariprazine on Psychosis: Beyond Schizophrenia – A Case Series

Neuropsychiatric Disease and Treatment, 2022
Miguel Bajouco,1– 3 David Mota1,2 1Department of Psychiatry, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; 2Institute of Psychological Medicine, Faculty of Medicine, University of Coimbra, Coimbra, Portugal; 3Coimbra Institute for ...
Bajouco M, Mota D
doaj  

Cariprazine as a useful treatment for patients with schizophrenia and antipsychotic-induced extrapyramidal symptoms: a case report and literature review

European Psychiatry, 2022
Introduction The discovery of second-generation antipsychotics represented an authentic breakthrough for the management of psychotic disorders. Nevertheless, they still don’t adequately manage some aspects of these disorders, such as negative symptoms ...
C. Llach, L. Ilzarbe, M. Sagué-Vilavella, N. Arbelo, R. Catalan, F. Gutierrez   +5 more
doaj   +1 more source

Cariprazine in Schizophrenia: Clinical Efficacy, Tolerability, and Place in Therapy [PDF]

, 2013
Cariprazine is a dopamine D3-preferring D3/D2 receptor partial agonist in late-stage clinical development for the treatment of schizophrenia, as well as for bipolar disorder (manic/mixed and depressive episodes), and as an adjunctive agent for the ...
Citrome, Leslie, Leslie Citrome
core   +1 more source

Cariprazine add-on in inadequate clozapine response: A report on two cases

, 2021
Cariprazine is a novel antipsychotic drug that exerts partial agonism of dopamine D2/D3receptors with preferential binding to the D3receptor, antagonism of 5HT2B receptors, and partial agonism of 5HT1A.
Giardini A., De Lauretis I., Iasevoli F., Trotta S., Rapini G., Olivieri L., Serroni N., De Berardis D., Vellante F., Alessandrini M., Di Giannantonio M., Fornaro M., Orsolini L., Cottura P.   +13 more
core   +2 more sources

Cariprazine in the treatment of psychosis with comorbid cannabis use: A case report

Psychiatry Research Communications, 2022
Past literature highlights that cannabis use increase the risk of developing psychotic disorder. In this case report, the authors describe the employment of cariprazine in the treatment of a young adult male affected by psychosis and co-morbid cannabis ...
Alessandro Gentile, Stefano Marini, Ilaria Matarazzo, Domenico De Berardis, Antonio Ventriglio   +4 more
doaj   +1 more source

Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?

Frontiers in Psychiatry, 2022
Dopamine receptor partial agonists (DRPAs; aripiprazole, brexpiprazole, and cariprazine) constitute a novel class of antipsychotics. Although they share a similar mechanism of action, DRPAs differ in their pharmacodynamics, pharmacokinetics, drug ...
Pavel Mohr, Pavel Mohr, Jirí Masopust, Miloslav Kopeček, Miloslav Kopeček   +4 more
doaj   +1 more source